Source comparison
Subcutaneous vs Intramuscular: Absorption Kinetics That Change Data Quality
Subcutaneous injection deposits MK-677 into the hypodermis. The fatty layer between skin and muscle. Where lower vascular density creates a gradual absorption profile. Pharmacokinetic studies show subcutaneous peptides reach peak plasma concentration (Cmax) in
This comparison does not assign a generated winner or score.
- Subcutaneous injection deposits MK-677 into the hypodermis. The fatty layer between skin and muscle. Where lower vascular density creates a gradual absorption profile. Pharmacokinetic studies show subcutaneous peptides reach peak plasma concentration (Cmax) in 90–120 minutes with a sustained plateau extending 6–8 hours post-injection. Intramuscular injection bypasses the adipose depot and delivers peptides directly into skeletal muscle tissue, where higher capillary density accelerates absorption. Cmax occurs 45–60 minutes post-IM injection, followed by a sharper decline.
- The practical difference for research: subcutaneous administration produces tighter confidence intervals when measuring downstream biomarkers (IGF-1, glucose homeostasis, lean mass accretion). If your protocol compares MK-677 effects across treatment arms, IM injection introduces a confounding variable. Peak exposure timing differs by 30–45 minutes depending on muscle group vascularity. Rotating IM sites across deltoid, vastus lateralis, and ventrogluteal areas compounds this variance because blood flow rates differ significantly between these regions.
- Our experience working with labs running multi-week MK 677 protocols shows consistent site selection eliminates one major source of noise. Researchers who stick to abdominal subcutaneous injection report cleaner dose-response curves and fewer outlier data points during analysis.